Onconetix (ONCO) Share-based Compensation (2021 - 2026)
Onconetix (ONCO) posted quarterly Share-based Compensation of $22305.0 for Q1 2026, down 23.76% year-over-year from $29256.0 in Q1 2025, and up 426.81% quarter-over-quarter from $4234.0 in Q4 2025.
Onconetix (ONCO) Share-based Compensation (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Share-based Compensation for 6 consecutive years, with $22305.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 23.76% year-over-year to $22305.0; the TTM figure through Mar 2026 stood at $67316.0 (down 84.16% YoY), while the FY2025 annual figure was $74267.0, down 83.07% from the prior year.
- Share-based Compensation grew to $22305.0 in Q1 2026 per ONCO's latest filing, from $4234.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.4 million in Q2 2022 and bottomed at -$1.5 million in Q4 2022.
- Historically, Share-based Compensation has averaged $100135.9 across 5 years, with a median of $45634.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 6435.14% — and 2025, when it surged 4097.68%.
- Onconetix's Share-based Compensation stood at -$1.5 million in 2022, then jumped by 121.52% to $329755.0 in 2023, then increased by 6.38% to $350789.0 in 2024, then slumped by 98.79% to $4234.0 in 2025, then surged by 426.81% to $22305.0 in 2026.
- Business Quant data shows ONCO's Share-based Compensation at $22305.0 in Q1 2026, $4234.0 in Q4 2025, and $9795.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Onconetix | 1.45 Mn | -4.50 Mn | 4,303.00 | 7,359.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,359.00 |
| Jun 30, 2026 | 7,359.00 |
| Mar 31, 2026 | 22,305.00 |
| Mar 31, 2026 | 22,305.00 |
| Dec 31, 2025 | 4,234.00 |
| Dec 31, 2025 | 4,234.00 |
| Sep 30, 2025 | 9,795.00 |
| Sep 30, 2025 | 9,795.00 |
| Jun 30, 2025 | 30,982.00 |
| Jun 30, 2025 | 30,982.00 |
| Mar 31, 2025 | 29,256.00 |
| Mar 31, 2025 | 29,256.00 |
| Dec 31, 2024 | 350,789.00 |
| Dec 31, 2024 | 350,789.00 |
| Sep 30, 2024 | 45,634.00 |
| Sep 30, 2024 | 45,634.00 |
| Jun 30, 2024 | -775.00 |
| Jun 30, 2024 | -775.00 |
| Mar 31, 2024 | 52,650.00 |
| Mar 31, 2024 | 52,650.00 |